Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 우현애 | * |
dc.date.accessioned | 2021-11-16T16:31:52Z | - |
dc.date.available | 2021-11-16T16:31:52Z | - |
dc.date.issued | 2021 | * |
dc.identifier.issn | 0007-0920 | * |
dc.identifier.other | OAK-30072 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/259552 | - |
dc.description.abstract | Background: Peroxiredoxin 1 (PRDX1) belongs to an abundant family of peroxidases whose role in cancer is still unresolved. While mouse knockout studies demonstrate a tumour suppressive role for PRDX1, in cancer cell xenografts, results denote PRDX1 as a drug target. Probably, this phenotypic discrepancy stems from distinct roles of PRDX1 in certain cell types or stages of tumour progression. Methods: We demonstrate an important cell-autonomous function for PRDX1 utilising a syngeneic mouse model (BALB/c) and mammary fibroblasts (MFs) obtained from it. Results: Loss of PRDX1 in vivo promotes collagen remodelling known to promote breast cancer progression. PRDX1 inactivation in MFs occurs via SRC-induced phosphorylation of PRDX1 TYR194 and not through the expected direct oxidation of CYS52 in PRDX1 by ROS. TYR194-phosphorylated PRDX1 fails to bind to lysyl oxidases (LOX) and leads to the accumulation of extracellular LOX proteins which supports enhanced collagen remodelling associated with breast cancer progression. Conclusions: This study reveals a cell type-specific tumour suppressive role for PRDX1 that is supported by survival analyses, depending on PRDX1 protein levels in breast cancer cohorts. © 2021, The Author(s), under exclusive licence to Springer Nature Limited. | * |
dc.language | English | * |
dc.publisher | Springer Nature | * |
dc.title | Peroxiredoxin-1 Tyr194 phosphorylation regulates LOX-dependent extracellular matrix remodelling in breast cancer | * |
dc.type | Article | * |
dc.relation.issue | 8 | * |
dc.relation.volume | 125 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 1146 | * |
dc.relation.lastpage | 1157 | * |
dc.relation.journaltitle | British Journal of Cancer | * |
dc.identifier.doi | 10.1038/s41416-021-01510-x | * |
dc.identifier.wosid | WOS:000684748400001 | * |
dc.identifier.scopusid | 2-s2.0-85112681564 | * |
dc.author.google | Attaran S. | * |
dc.author.google | Skoko J.J. | * |
dc.author.google | Hopkins B.L. | * |
dc.author.google | Wright M.K. | * |
dc.author.google | Wood L.E. | * |
dc.author.google | Asan A. | * |
dc.author.google | Woo H.A. | * |
dc.author.google | Feinberg A. | * |
dc.author.google | Neumann C.A. | * |
dc.contributor.scopusid | 우현애(8068619500) | * |
dc.date.modifydate | 20240215164922 | * |